Discover the EmbracePlus Actigraphy sensor modes for optimal activity, sleep, and motion data collection

Empatica

On-demand Webinar: Unlock the future of real-world research with Dr. Rosalind Picard. Watch it now!

embrace for research

Decentralize your trials with digital endpoints and a powerful end-to-end platform

EmbracePlus

Using industry-leading wearable devices, collect data remotely with instant access through an intuitive online portal. Conducting trials at scale from patients’ homes has never been easier.

Get started

A complete platform for decentralized, virtual, and hybrid clinical trials

Embrace for Research is a fully integrated platform for conducting real-world trials across multiple sites. Empatica’s powerful Embrace2 and EmbracePlus wearables can continuously and accurately record and send physiological information to the cloud, enabling virtually unlimited data and scalability. And through the Research Portal, researchers can cost-effectively conduct multi-site studies and analyze data remotely and securely, accelerating their findings and reducing costs.

Multi-site studies

Build a research team and check the progress of multiple sites at a glance

Team management

Each study or site created is isolated, you can fine-tune access levels for each team member

Easy set-up

By deploying a one-time-use QR code scan, we simplify subject enrollment while ensuring that there are no ID errors

Optimal research platform

Review deployed device status and monitor subject compliance in real time

SLEEP APNEA STUDY

Sleep Revolution H2020

The Sleep Revolution, an interdisciplinary international research and development project, aims to develop a smart, personalized diagnostic and therapeutic solution for sleep-disordered breathing (sleep apnea). Using the EmbracePlus smartwatch, the study entails developing Machine Learning models to determine the severity and treatment needs of people with sleep apnea, for accurate diagnosis and improved treatment.

ADHD STUDY

Timespan H2020

TIMESPAN, a consortium of 17 institutions from 14 countries has launched the ART-CARMA project, to study the management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients. Using EmbracePlus, the project aims to understand the risks of cardiometabolic illnesses such as cardiovascular disease and obesity for adults with ADHD, and how their future health can best be improved through medication.

DIGITAL ENDPOINT VALIDATION STUDY

VeraSci

VeraSci’s Innovation Lab has been conducting an NIH-funded study examining the relationship between real-time measurements of gait and actigraphy, collected by the Embrace2, and established cognitive and functional endpoints that are sensitive to decline early in the Alzheimer’s disease continuum. Their preliminary data suggest a positive correlation between in-clinic measurements and the endpoints developed using Embrace2 data for monitoring the patient's cognitive health.

Download the case study

DRUG EFFICIENCY TRIAL

Sunovion Pharmaceuticals

Sunovion Pharmaceuticals utilized Empatica Health Monitoring Platform during their international multi-site phase-4 anti-epileptic drug trial. Empatica’s FDA-cleared seizure detection algorithm and the e-diary app allowed Sunovion to continuously monitor patients, gaining an objective insight into seizure counts while remotely monitoring compliance throughout the study.

FLU PREVENTION STUDY

Biomedical Advanced Research and Development Authority

The US government’s Biomedical Advanced Research and Development Authority (BARDA) has partnered with Empatica to develop a digital endpoint for detecting the earliest signs of the flu. Through the use of the Embrace2 wearable and Empatica data analysis expertise, they engaged in a prospective study monitoring healthy individuals throughout the flu season with the aim to develop an early detection system. Following the outbreak of the Covid-19 pandemic, BARDA and Empatica renewed their partnership to utilize EmbracePlus and the Care suite for Covid-19 early detection.

MENTAL HEALTH STUDY

Harvard University

Harvard University Clinical Psychologist Dr. Matthew K. Nock is using Embrace for Research to detect digital phenotypes related to suicidal thoughts in a multi-site study involving hundreds of individuals wearing Embrace2. This is the largest-yet study about suicidal behavior also measuring skin conductance levels as an objective way to assess changes in physiological distress in the participants.

BIOFEEDBACK

4YouandMe

4YouandMe, a non-profit company founded by Dr. Stephen H. Friend has partnered with clinicians at Oxford University and Mount Sinai School of Medicine to conduct a multi-site prospective cohort study, utilizing Empatica wearables to monitor signs of stress and symptoms of Crohn's disease. The aim of this project is to provide biofeedback to patients with Crohn’s, in order to potentially prevent negative clinical changes in their condition.

ZERO GRAVITY STUDY

MIT Media Lab

MIT Media Lab’s doctoral student, Kristina T. Johnson has embarked on a journey to measure autonomic changes in parabolic flyers. Parabolic flight planes are notorious for inducing high levels of nausea. By using Empatica’s technology and other biosignal measures, Kristy and her team were able to gain an objective insight into novice and veteran flyers’ physiological well-being during flights.

DIGITAL THERAPEUTICS

Pear Therapeutics

Pear Therapeutics, the leader in prescription digital therapeutics, is using Empatica’s technology to explore using wearable sensors in the evaluation of withdrawal symptoms in patients with substance use disorder (SUD), opioid use disorder (OUD), and alcohol use disorder (AUD). Using the EmbracePlus smartwatch, Pear Therapeutic aims to integrate real-time personalization of digital therapeutic content and pharmaceutical dosing to patients across disease stages.

How does Embrace for Research work?

Embrace2
Embrace2
Embrace2's sensors measure physiological parameters including electrodermal activity, motion, and skin temperature, which are continuously sent via Bluetooth® to the Mate App
Mate
Mate
The Mate App automatically transfers the received Embrace data and diary entries to Empatica's cloud. A subset of the processed data are visualized in the app's 24-hours wheel
Research Portal
Research Portal
Through the Research Portal you can manage your studies and access raw and processed data received from the subjects
fda-cleared

embrace2

Continuous and accurate participant data

embrace2

A medical-grade wearable to continuously measure physiological parameters, giving insights into sleep, activity, autonomic arousal, and seizures for many different typologies of clinical/research studies.

Patented technology

Patented technology

Collect objective biometric data

Clinical-grade sensors

Clinical-grade sensors

EDA, PPG, Accelerometer and Gyroscope

Non-stop data collection

Non-stop data collection

Thanks to sophisticated sensors, on-board memory and continuous data streaming

Continuous monitoring of the Sympathetic Nervous System

Continuous monitoring of the Sympathetic Nervous System

The only smartwatches to offer continuous EDA data streaming

Award-winning design

Award-winning design

Maximum comfort and wearability, to improve subject recruitment, retention, and compliance

Technical specifications

EDA Sensor

  • Sampling frequency: 4Hz (fixed)
  • Resolution: 55 fSiemens
  • Range: 0 μSiemens - 80μ - 80 e:
  • AC excitation, 4Hz, max.
  • Electrodes (applied parts):
  • Placement on either the ventral (inner) wrist or dorsal (outer) wrist.

Temperature Sensor

  • Sampling frequency: 1Hz
  • Range: -20ºC to 70ºC
  • Resolution: 0.15ºC
Technical specifications

3-Axis accelerometer

  • Sampling frequency: 32Hz
  • High sensitivity motion detection on 3 axes:
  • Range ± 16g.
  • Resolution: 16 bits

Gyroscope

  • Sampling frequency: 32Hz
  • High sensitivity motion detection on 3 axes
  • Range ± 500 degrees/sec.
  • Resolution: 16 bits

Mate App

An end to paper diaries

Mate App

The Mate App keeps participants engaged while it collects, visualizes, and transmits device data to the Research Portal, where you can review it at a glance.

  • Safeguard participant engagement through a simple, user-friendly app.
  • Complement device data with self-reporting from participants, via daily e-diary entries, that can provide insights for understanding subjective outcomes.
  • Encourages patients to stay engaged throughout your study by visualizing their sleep and activity data.
  • Secure and reliable data transfer and visualization. A unique identifier also ensures that the subject’s data is partitioned correctly and stored securely.
hiipa compliant

Research Portal

Easily manage and access data from multiple sites and studies

Research Portal

The Research Portal allows research teams, CRO personnel, and study coordinators to visualize, monitor, and download data from different types of longitudinal and clinical studies on the cloud.

Take a look
Maintain full control

Maintain full control

Manage investigations, check compliance, manage multiple sites, and collect data from different types of research studies, all within one platform

Build your own team

Build your own team

Create a flawlessly organized hierarchy and easily delegate tasks (e.g. enrollment, data collection) with the Research Portal

Go global

Go global

Easy management of sites, studies, and teams, enabling global teamwork and easy remote subject enrollment and management

Easily customizable

Easily customizable

Customize the platform according to your research needs (such as type of research, type of data or events that need to be collected)

Gain full visibility raw data

Gain full visibility raw data

Instantly access and download raw data from all devices

Discover how Embrace2 for Research can empower your study

Potential savings per patient

Using Electronic Data Capture (EDC) can result in significant savings throughout all the phases of clinical trials. This graph illustrates an estimation of how much a pharmaceutical company can save per patient in each phase if using a solution like Empatica’s.

Phase I
Phase II
Phase III
Phase I

Total saving per patient 
(Phase I)

$367

Total saving per patient 
(Phase I and II)

$6,274

Total saving per patient 
(Phase I, II and III)

$12,869
Support at every step of the way

Support at every step of the way

The Empatica promise:

  • All our clients benefit from detailed and dedicated onboarding, including an account manager and site support to walk you through every step of the process
  • We handle the logistics and provide IRB materials so you can focus on your research
  • Dedicated customer and technical support
  • Start collecting data in less than 5 minutes with auto-generated QR codes for participant enrollment

Meeting global safety and security standards

What is your multi-site research goal?

Talk with our experts to discover how Embrace for Research can empower your investigation.

Talk to our team

FDA clearance is limited to use for seizure alerting as an adjunct to seizure monitoring of adults and children of age 6 and up in home or healthcare facilities during period of rest. For more information please refer to FDA Clearance Summary. Battery performance is subject to variability and might degrade over time.
Embrace2 is classified as IP67, resistant to submersion in 1m (about 3.3 feet) of water for up to 30 minutes. The device is not intended to be worn in salt water or hot-tubs.
Each Embrace2 needs to be paired with one iOS or Android mobile device running the Mate app. Bluetooth® 4.0 low energy and WiFi/cellular internet connectivity are required on the paired device in order to upload Embrace2 sensor data to Empatica servers. For more information please check the dedicated support articles.

Your Cart

Your cart is currently empty.

Go to Store
ItemPrice (USD)
X

Select your Location

If you do not see your country listed, please visit the International site.
Please note that Embrace Alert System is not available in the following countries .